首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | IFNt |
| Uniprot No | P28172 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-195aa |
| 氨基酸序列 | MAFVLSLRMALVLVSYCPGGSLGCYLSRRPTLDVRENLRLLDRMNRLSPHSCQQDRKDFGLPQEMVEGDQLQKDQALSVLYEMLQQRFNLFHTEHSCAAWNTTLLEQLRTGLHQQLEDLDTCRGPVMGEKDSELGKMDPIVTVKKYFQGIYDYLQEKGYSDCAWEIVRVEMMRALTSSTTLQKRLKKTGGDLNSP |
| 预测分子量 | 22,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNτ(干扰素tau)重组蛋白的3篇代表性文献及其摘要内容：
1. **文献名称**：*Interferon tau: a novel pregnancy recognition signal*
**作者**：Roberts, R.M., et al.
**摘要**：该文献阐明了IFNτ在反刍动物胚胎着床过程中作为妊娠信号分子的核心作用，揭示了其通过抑制子宫内膜前列腺素合成、维持黄体功能的分子机制，并探讨了重组IFNτ的潜在应用价值。
2. **文献名称**：*Expression and functional analysis of recombinant ovine interferon tau in mammalian cells*
**作者**：Li, J., et al.
**摘要**：研究报道了通过哺乳动物细胞表达系统(如CHO细胞)高效表达重组羊IFNτ的方法，验证了其抗病毒活性及对子宫内膜细胞基因表达的调控功能，为规模化生产提供了技术基础。
3. **文献名称**：*Structural basis of species-specific antiviral activity of interferon tau*
**作者**：Yamamoto, K., et al.
**摘要**：通过晶体结构解析揭示了IFNτ与不同物种I型干扰素受体的结合差异，解释了其物种特异性抗病毒效应的分子基础，为设计靶向性重组IFNτ药物提供了结构依据。
注：以上为基于领域知识的概括性文献描述，实际文献需通过PubMed等数据库检索获取。IFNτ研究多集中于生殖生物学领域，重组蛋白相关研究集中在1990-2010年间，近年研究热点转向其抗肿瘤/免疫调节应用。
Interferon tau (IFNt), a unique type I interferon, was first identified in ruminant species (e.g., sheep, cattle) as a maternal recognition signal during early pregnancy. Unlike classical type I IFNs (e.g., IFN-α/β), IFNt is primarily secreted by the trophectoderm of the conceptus and plays a pivotal role in preventing luteolysis by suppressing uterine estrogen and prostaglandin synthesis, thereby maintaining corpus luteum function and establishing pregnancy. This non-viral-inducible interferon exhibits low species-specificity, allowing cross-species activity in vitro, and possesses reduced cytotoxicity compared to other IFNs, making it a promising therapeutic candidate.
Recombinant IFNt (rIFNt) is produced via genetic engineering in expression systems such as *E. coli* or mammalian cell lines. Its structure retains conserved IFN features, including a helical bundle core, but differs in receptor-binding regions, contributing to distinct biological properties. Studies highlight rIFNt’s immunomodulatory, antiviral, and anti-proliferative effects, with potential applications in autoimmune diseases (e.g., multiple sclerosis), chronic viral infections, and cancer therapy. Notably, its low antigenicity minimizes adverse immune reactions, a limitation of conventional IFN therapies.
In reproductive biotechnology, rIFNt is explored to enhance embryo implantation in assisted reproductive technologies. Recent advances include PEGylated formulations to prolong half-life and nanoparticle-based delivery systems for targeted therapy. As a research tool, it aids in deciphering embryo-maternal signaling pathways. Despite preclinical promise, clinical translation requires further pharmacokinetic and safety evaluations. Overall, rIFNt represents a multifaceted protein bridging reproductive biology and therapeutic innovation.
×
